Merck Stock ( NYSE:MRK )
In addition to breaking ground on a new factory in Singapore that would make inhalers, Merck ( NYSE:MRK ) said on October 5 that it had launched a new secondary packaging facility to support the manufacturing of vaccines and biologics, including immunotherapies. As a result, Merck stock surged in the market.
Merck’s ( NYSE:MRK ) investment, which will total up to $500 million over the next five years and begin in 2020, will include constructing the production facilities.
1997 marked the beginning of Merck’s ( NYSE:MRK ) manufacturing activities in Singapore. The facilities may be found inside an existing industrial cluster that encompasses 72 acres and is situated in Tuas, Singapore.
The semi-automated vial-packaging line will produce the Merck stock blockbuster cancer drug Keytruda (pembrolizumab), and the fully automated syringe-packaging lines will be used to produce the HPV vaccine Gardasil 9. The secondary packaging facility will have a total of four semi-automated packaging lines.
In the previous year, the location had initiated the sterile filling procedure for Keytruda. According to a news statement issued by the firm on October 5, the expansion has resulted in the addition of secondary packaging, cold storage, and a quality control laboratory.
Merck stock also said that the new inhaler medicine plant, scheduled to be completed in the year 2026, would develop inhalation devices for the next generation for the targeted administra...
Click here to read the full article on PressReach.com .Subscribe to the PressReach RSS feeds:
- Featured News RSS feed
- Investing News RSS feed
- Daily Press Releases RSS feed
- Trading Tips RSS feed
- Investing Videos RSS feed
Follow PressReach on Twitter
Subscribe to us on Youtube
PressReach Disclaimer .